The vagus nerve is a long nerve that runs from the brainstem to the abdomen. It plays a role in regulating many bodily functions, including heart rate, blood pressure, and digestion. Vagus nerve stimulation (VNS) is a medical procedure that involves implanting a device that sends electrical pulses to the vagus nerve. This therapy has been shown to be effective in treating a variety of neurological disorders, including epilepsy, depression, and migraine. VNS therapy is a safe and effective treatment for a variety of neurological disorders. It is a minimally invasive procedure that has the potential to improve the quality of life for many patients.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-vagus-nerve-stimulation-market
Data Bridge Market Research analyses that the Vagus Nerve Stimulation Market will grow at a CAGR of 15.00% in the forecast period of 2022 to 2029 and is expected to reach USD 2,424.01 million by 2029 from USD 792.41 million in 2021. Governments around the world are investing in VNS initiatives in order to improve the quality, efficiency, and affordability of healthcare. These initiatives are creating new opportunities for VNS companies to develop and market their products and services. Technological advancements such as the development of smaller and more powerful implantable devices are making VNS therapy more accessible and affordable. Patients are increasingly demanding VNS therapy as a treatment option for their neurological disorders.
Growing number of neurological disorders is expected to drive the market's growth rate
Neurological disorders are a major cause of disability and death worldwide. The prevalence of these disorders is expected to increase in the coming years, due to factors such as aging, obesity, and environmental factors. VNS is a minimally invasive procedure, making it an attractive option for patients reluctant to undergo traditional surgery. VNS therapy has shown promising results in treating various neurological disorders, including epilepsy, depression, and migraine.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymeric), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgery Centres, Specialty Centers, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Medtronic (Ireland), LivaNova PLC (U.S.), electroCore, Inc. (U.S.), Cirtec (U.S.), Brain Control Co. Limited (U.K.), Soterix Medical Inc. (U.S.), SetPoint Medical (U.S.), MicroTransponder Inc. (U.S.), Parasym Ltd. (U.K.), and tVNS Technologies GmbH (Germany)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global vagus nerve stimulation market is categorized into six notable segments based on product type, biomaterial, application, patient type, end user, and distribution channel.
- Based on product type, the market is segmented into implantable VNS devices and external VNS devices. Implantable VNS devices segment is expected to dominate the market with 64.66% market share as it provides efficacy benefits in small studies in refractory migraine and cluster headaches.
- Based on biomaterial, the market is segmented into ceramics, metallic, and polymeric. Metallic segment is expected to dominate the market with 54.64% market share due to its high strength, high fracture toughness, hardness, corrosion resistance, and biocompatibility.
- Based on application, the market is segmented into pain management, epileptic seizures, obesity management, depression and anxiety, and others. Epileptic seizures segment is expected to dominate the market with 48.26% market share due to rise in brain injuries, neurodevelopmental problems, and genetic predispositions.
- Based on patient type, the market is segmented into adults, pediatrics, and geriatrics. Adults segment is expected to dominate the market with a 60.82% market share due to the increased prevalence of neurological disorders.
- Based on end user, the market is segmented into hospitals, ambulatory surgical centers, and specialty centers. Specialty centers segment is expected to dominate the market with 51.09% market share due to the increasing application areas and the rising number of government initiatives.
The hospitals segment will dominate the end user segment of the vagus nerve stimulation market
The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- Based on distribution channel, the market is segmented into direct tender, retail sales, and others. Direct tender segment is expected to dominate the market with 55.46% market share as it creates opportunities and competition in the market and provides a high level of transparency, and distribution of the medical devices are the factors that are expected to drive the market growth.
The direct tender segment will dominate the distribution channel segment of the vagus nerve stimulation market
The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Medtronic (Ireland), LivaNova PLC (U.S.), electroCore, Inc. (U.S.), Cirtec (U.S.), Brain Control Co. Limited (U.K.), Soterix Medical Inc. (U.S.), SetPoint Medical (U.S.), MicroTransponder Inc. (U.S.), Parasym Ltd. (U.K.), and tVNS Technologies GmbH (Germany).
Market Development
- In 2021, MicroTransponder Inc. announced that the U.S. Food and Drug Administration (FDA) had approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke. The Vivistim System is a small, implantable device that delivers mild electrical pulses to the vagus nerve, which helps to improve movement and function in the affected arm. After receiving FDA approval, MicroTransponder began commercializing the Vivistim System in the United States. The company has since reported strong sales of the device, with revenue from Vivistim sales increasing by 50% in the first quarter of 2023.
- In 2022, Healthtech startup Pulsetto launched a neuromodulation device that stimulates the vagus nerve. The Pulsetto device is a small, wearable device that delivers mild electrical pulses to the vagus nerve, which helps to improve mood, reduce stress, and promote relaxation. The Pulsetto device is based on the principle of vagus nerve stimulation (VNS), which is a minimally invasive therapy that has been shown to be effective in treating a variety of conditions, including epilepsy, depression, and anxiety. VNS works by stimulating the vagus nerve, which is a major nerve that runs from the brain to the stomach.
- In 2019, Electrocore Inc. received FDA approval for gammaCore (nVNS), an nVNS device that is used to treat migraine headaches. The gammaCore device is a small, handheld device that delivers a short burst of electrical stimulation to the vagus nerve. The stimulation is designed to block the transmission of pain signals to the brain. The gammaCore device is a non-invasive alternative to traditional migraine treatments, such as medication and surgery. The device is easy to use and can be used at home or on the go. Electrocore has reported that the gammaCore device has been well-received by patients, and the company is working to expand the device's availability to patients worldwide.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the vagus nerve stimulation market during the forecast period 2022-2029
North America dominated the global VNS market. The region is expected to continue to dominate the market during the forecast period, owing to the increasing prevalence of epilepsy and depression in the region. The United States is the largest market for VNS in the Americas, followed by Canada and Mexico.
Asia-Pacific is estimated to be the fastest growing region in the vagus nerve stimulation market in the forecast period 2022-2029
Asia-Pacific is expected to be the fastest-growing market for VNS during the forecast period. The growth of the market in Asia Pacific is attributed to the rising prevalence of epilepsy and depression in the region, as well as the increasing acceptance of minimally invasive therapies. China, India, and Japan are the leading markets for VNS in Asia-Pacific.
For more detailed information about the vagus nerve stimulation market report, click here – https://www.databridgemarketresearch.com/reports/global-vagus-nerve-stimulation-market
